CD 24 in Melanoma: Biomarker, Innate Immune Checkpoint and Emerging Therapeutic Target

Documenti analoghi

• Review of Low‐Dose Naltrexone for Hailey–Hailey Disease Suggests Lack of Benefit in Dose Escalation
  di: Yulu Wang, et al.
  Pubblicazione: (2026)
• C‐Reactive Protein Kinetics as Prognostic Biomarkers in Stage IV ‐Melanoma Treated With Immune Checkpoint Inhibitors in the Japanese Population: A Single‐Center, Retrospective Cohort Study
  di: Ken Horisaki, et al.
  Pubblicazione: (2025)
• Extended‐Interval Dosing of an Immune Checkpoint Inhibitor Following a Complete Response in Melanoma: A Case Report
  di: Yoshiyuki Matsui, et al.
  Pubblicazione: (2025)
• Clinical Outcomes of Dacarbazine After Failure of Immune Checkpoint Inhibitors: A Case Study of 15 Japanese Patients With Malignant Melanoma
  di: Ken Horisaki, et al.
  Pubblicazione: (2026)
• Clinical Features of Nasal and Paranasal Mucosal Melanomas in the Era of Immune Checkpoint Inhibitors: Insights From a Single‐Institution Analysis
  di: Yuma Waki, et al.
  Pubblicazione: (2026)